02197 PE Ratio & Valuation, Is 02197 Overvalued

Historical Valuation

CLOVER BIO-B (02197) is now in the Overvalued zone, suggesting that its current forward PS ratio of 3.90 is considered Overvalued compared with the five-year average of 9.66. The fair price of CLOVER BIO-B (02197) is between 0.24 to 2.24 according to relative valuation method. Compared to the current price of 2.89 USD , CLOVER BIO-B By Overvalued By 29%.

Relative Value

Fair Zone

0.24-2.24

Current Price：2.89

29%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is CLOVER BIO-B (02197) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

CLOVER BIO-B (02197) has a current Price-to-Book (P/B) ratio of -1.71. Compared to its 3-year average P/B ratio of 8.68, the current P/B ratio is approximately -119.66% higher. Relative to its 5-year average P/B ratio of 8.26, the current P/B ratio is about -120.66% higher. CLOVER BIO-B (02197) has a Forward Free Cash Flow (FCF) yield of approximately -8.93%. Compared to its 3-year average FCF yield of -102.59%, the current FCF yield is approximately -91.30% lower. Relative to its 5-year average FCF yield of -78.98%, the current FCF yield is about -88.69% lower.

Performance Decomposition

AI Analysis

Market capitalization of 02197 increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of 02197 in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is 02197 currently overvalued or undervalued?

What is CLOVER BIO-B (02197) fair value?

02197's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of CLOVER BIO-B (02197) is between 0.24 to 2.24 according to relative valuation method.

How does 02197's valuation metrics compare to the industry average?

The average P/S ratio for 02197's competitors is 0.00, providing a benchmark for relative valuation. CLOVER BIO-B Corp (02197) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for CLOVER BIO-B (02197) as of Apr 03 2026?

As of Apr 03 2026, CLOVER BIO-B (02197) has a P/B ratio of -1.71. This indicates that the market values 02197 at -1.71 times its book value.

What is the current FCF Yield for CLOVER BIO-B (02197) as of Apr 03 2026?

As of Apr 03 2026, CLOVER BIO-B (02197) has a FCF Yield of -8.93%. This means that for every dollar of CLOVER BIO-B's market capitalization, the company generates -8.93 cents in free cash flow.

What is the current Forward P/E ratio for CLOVER BIO-B (02197) as of Apr 03 2026?

As of Apr 03 2026, CLOVER BIO-B (02197) has a Forward P/E ratio of 56.10. This means the market is willing to pay $56.10 for every dollar of CLOVER BIO-B's expected earnings over the next 12 months.

What is the current Forward P/S ratio for CLOVER BIO-B (02197) as of Apr 03 2026?

As of Apr 03 2026, CLOVER BIO-B (02197) has a Forward P/S ratio of 3.90. This means the market is valuing 02197 at $3.90 for every dollar of expected revenue over the next 12 months.

02197 Valuation